
CG Oncology reported a 68% lower recurrence risk in a Phase 3 trial and outlined plans for two bladder-cancer submissions.
CG Oncology said its Phase 3 PIVOT-006 trial met its primary endpoint, with cretostimogene reducing the risk of recurrence by 68% versus the control arm. The company reported a hazard ratio of 0.32 and said the topline results were based on a median follow-up of 17 months.
The company said there were no treatment-related adverse events of Grade 3 or higher and no treatment-related discontinuations. The candidate is investigational, and its safety and efficacy have not been established by the FDA.
CG Oncology plans to complete its initial BLA submission for BCG-unresponsive disease by the end of March 2027, broadened to include high-grade papillary-only disease. It expects a second submission for intermediate-risk and high-grade Ta disease in the second quarter of 2027.
This article was produced with the help of AI technology. Based on reporting by the outlets listed above.